Rex CFA - Anebulo Pharmaceuticals CFO Sec
| ANEB Stock | USD 1.40 0.06 4.11% |
Insider
Rex CFA is CFO Sec of Anebulo Pharmaceuticals
| Age | 64 |
| Address | 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734 |
| Phone | 512 598 0931 |
| Web | https://www.anebulo.com |
Anebulo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6597) % which means that it has lost $0.6597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.138) %, meaning that it created substantial loss on money invested by shareholders. Anebulo Pharmaceuticals' management efficiency ratios could be used to measure how well Anebulo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -2.11. The current year's Return On Capital Employed is expected to grow to -2.07. At present, Anebulo Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 510.5 K, whereas Total Assets are forecasted to decline to about 3.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Lori CPA | Lumos Pharma | 40 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| David MBA | Seres Therapeutics | 63 | |
| Bradley JD | Lumos Pharma | 45 | |
| BBA CPA | Lumos Pharma | 57 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Hing Wong | HCW Biologics | 70 | |
| Jeff York | Seres Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 |
Anebulo Pharmaceuticals Leadership Team
Elected by the shareholders, the Anebulo Pharmaceuticals' board of directors comprises two types of representatives: Anebulo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anebulo. The board's role is to monitor Anebulo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Anebulo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anebulo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rex CFA, CFO Sec | ||
| Daniel George, Acting Officer | ||
| Richard Cunningham, CEO Director | ||
| Scott Anderson, Head Affairs | ||
| Kenneth Cundy, Chief Officer |
Anebulo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anebulo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 36.46 M | ||||
| Shares Outstanding | 25.93 M | ||||
| Shares Owned By Insiders | 64.22 % | ||||
| Shares Owned By Institutions | 28.18 % | ||||
| Number Of Shares Shorted | 10.76 K | ||||
| Price To Book | 19.94 X | ||||
| EBITDA | (8.05 M) | ||||
| Net Income | (8.2 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (0.66) | Return On Equity (1.14) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.